Eli Lilly and Company: Pancreatic Neoplasms trials
The registry lists 25 Pancreatic Neoplasms studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 11 have results posted.
Phase 1 14Phase 2 12Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
- A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerCompletedNCT04148937Phase 1Results posted
- A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic CancerCompletedNCT03086369Phase 1/2Results posted
- A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal AdenocarcinomaCompletedNCT02981342Phase 2Results posted
- Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic CancerCompletedNCT02923921Phase 3Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic CancerTerminatedNCT01632306Phase 1/2Results posted
- A Phase 2 Study of LY2495655 in Participants With Pancreatic CancerCompletedNCT01505530Phase 2Results posted
- A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic CancerCompletedNCT01373164Phase 1/2Results posted
- A Study for Participants With Pancreatic CancerCompletedNCT00839332Phase 1/2Results posted
- Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic CancerTerminatedNCT00326911Phase 2Results posted
- Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic CancerCompletedNCT00267020Phase 2Results posted
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2
- Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationApproved for marketingNCT03906331
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedNCT02791334Phase 1
- A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerCompletedNCT02734160Phase 1
- A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the BodyCompletedNCT02154646Phase 1
- Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is MetastaticCompletedNCT00490373Phase 2
- Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic CancerCompletedNCT00191568Phase 2
- A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic CancerCompletedNCT00055250Phase 2
- A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.CompletedNCT00035035Phase 3